Media Release
An Australian-Singaporean bone and tissue regeneration company will soon be helping US military veterans suffering trauma injuries and congenital defects with its ground-breaking 3D-printed bone regenerative implants.
Osteopore’s US-based distributor, Bioplate Inc, has secured a non-exclusive distribution agreement with MellingMedical LLC which will see its FDA-cleared products sold to healthcare facilities operated by the US federal government – at more than 500 locations across the country.
The initial focus will be supplying products to the Veteran’s Affairs and Department of Defense facilities that have neuro and trauma surgery capabilities.
Under the terms, MellingMedical will market Osteopore’s FDA-cleared products to the healthcare facilities both domestically and internationally.
Osteopore Executive Chairman, Mark Leong said the company was pleased to be helping US military veterans with its ground-breaking technology, while expanding into a key market.
“This is an important and progressive milestone in the execution of our strategy of extending our presence in a key market like the USA,” said Mr Leong.
“Working closely with MellingMedical, we now have inroads to their wide and considerable access to VA-related medical facilities and clinics throughout USA and helps extend the footprint of our products. We are all enthused with this latest development and credit the team for imprinting Osteopore as a viable solution in the USA cranial market.”
Osteopore works with 3D-printed bioresorbable implants – whereby a scaffold guides a damaged or broken bone to regrow naturally.
The Australian and Singapore-based company has successfully developed and commercialised scaffold-guided bone regenerative implants for surgical use, reducing post-surgery complications compared to permanent alloy or titanium implants.
Bioplate CEO, Thomas Hopson, said: “We are excited about this agreement because it allows the VA, military hospitals, and other government facilities an opportunity to have access this novel technology. The Osteopore products address a clinical need that has not been solved with traditional cranial closure products.”
Founder and CEO of MellingMedical, Chris Melling, said, “We are amazed at the efficacy of Osteopore’s solutions and their ability to enhance and accelerate the body’s natural regenerative processes. Their technology’s potential to improve the quality of life for patients recovering from injury or even congenital skeletal defects is a game changer.”
MellingMedical offers federal healthcare agencies a range of healthcare products, with a focus on providing military veterans better access to quality and cost-effective medical equipment, supplies and pharmaceuticals.
MellingMedical has access to more than 165 Veteran’s Affairs (VA) Medical Centers, 300 VA Outpatient Clinics, all 7 Consolidated Mail Outpatient Pharmacies, and 95 Department of Defense Medical Facilities.
Bioplate and Osteopore will work with MellingMedical to apply for listing in the Federal Supplies Schedule (FSS). Upon successful listing confirmation, anticipated within six months, Osteopore products will be available to all federal healthcare facilities. Bioplate will appoint sales representatives to exclusively work with MellingMedical to promote Osteopore products across their network.
Osteopore and Bioplate will also work closely with MellingMedical, to train and support Bioplate’s sales representatives to facilitate ongoing promotion at targeted neuro-trauma centers across federal healthcare facilities.
